Hepatitis C virus (HCV) infection is characterized by a high propensity for development of life-long viral persistence. An estimated 170 million people suffer from chronic hepatitis caused by HCV. Currently, there is no approved prophylactic HCV vaccine available. With the near disappearance of the most relevant animal model for HCV, the chimpanzee, we review the progression that has been made regarding prophylactic vaccine development against HCV. We describe the results of the individual vaccine evaluation experiments in chimpanzees, in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved, but a clear correlate of protection has thus far not yet been defined.

Antibodies, Chimpanzees, Hepatitis C virus, Prophylactic, Review, T-cells, Vaccines
dx.doi.org/10.4254/wjh.v7.i1.53, hdl.handle.net/1765/81308
World Journal of Hepatology
Department of Gastroenterology & Hepatology

Verstrepen, B.E, Boonstra, P.A, & Koopman, G. (2015). Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World Journal of Hepatology, 7(1), 53–69. doi:10.4254/wjh.v7.i1.53